Literature DB >> 11866182

Effects of nicotine dose, instructional set, and outcome expectancies on the subjective effects of smoking in the presence of a stressor.

Laura M Juliano1, Thomas H Brandon.   

Abstract

The balanced placebo design (BPD) was used to evaluate the independent effects of nicotine dose and smoking-related expectancies on self-reported anxiety, urge to smoke, and withdrawal symptoms. After anxious mood was induced, participants smoked either a de-nicotinized cigarette or one with standard nicotine content. Nicotine dose was crossed with instructions that the cigarette was either de-nicotinized or standard. Nicotine cigarettes produced greater anxiety reduction than de-nicotinized cigarettes. Nicotine instructions attenuated anxiety only among those who held relevant expectancies. Nicotine dose and instructional set interacted such that either nicotine cigarettes or instructions that the cigarettes contained nicotine were sufficient to reduce urge to smoke. Implications of these findings and methodological issues regarding use of the BPD with cigarettes are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866182     DOI: 10.1037//0021-843x.111.1.88

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  50 in total

Review 1.  Anxiety, depression, and cigarette smoking: a transdiagnostic vulnerability framework to understanding emotion-smoking comorbidity.

Authors:  Adam M Leventhal; Michael J Zvolensky
Journal:  Psychol Bull       Date:  2014-11-03       Impact factor: 17.737

Review 2.  A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features.

Authors:  Laura M Juliano; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2004-09-21       Impact factor: 4.530

3.  Cognitive reappraisal and expressive suppression emotion regulation strategies in cigarette smokers.

Authors:  Lisa M Fucito; Laura M Juliano; Benjamín A Toll
Journal:  Nicotine Tob Res       Date:  2010-09-09       Impact factor: 4.244

4.  Expectancy and pharmacology influence the subjective effects of nicotine in a balanced-placebo design.

Authors:  William L Kelemen; Farnaz Kaighobadi
Journal:  Exp Clin Psychopharmacol       Date:  2007-02       Impact factor: 3.157

5.  An integrated approach to panic prevention targeting the empirically supported risk factors of smoking and anxiety sensitivity: theoretical basis and evidence from a pilot project evaluating feasibility and short-term efficacy.

Authors:  Matthew T Feldner; Michael J Zvolensky; Kimberly Babson; Ellen W Leen-Feldner; Norman B Schmidt
Journal:  J Anxiety Disord       Date:  2008-01-11

6.  Linkages between cigarette smoking outcome expectancies and negative emotional vulnerability.

Authors:  Kirsten A Johnson; Michael J Zvolensky; Erin C Marshall; Adam Gonzalez; Kenneth Abrams; Anka A Vujanovic
Journal:  Addict Behav       Date:  2008-05-14       Impact factor: 3.913

7.  Stimulus and Response Expectancies Influence the Cognitive Effects of Cigarettes.

Authors:  William L Kelemen
Journal:  J Smok Cessat       Date:  2008

8.  Perceived medication assignment during a placebo-controlled laboratory study of varenicline: temporal associations of treatment expectancies with smoking-related outcomes.

Authors:  John B Correa; Bryan W Heckman; Nicole S Marquinez; David J Drobes; Marina Unrod; Richard G Roetzheim; Thomas H Brandon
Journal:  Psychopharmacology (Berl)       Date:  2014-01-10       Impact factor: 4.530

9.  Nicotine or expectancies? Using the balanced-placebo design to test immediate outcomes of vaping.

Authors:  Amanda M Palmer; Thomas H Brandon
Journal:  Addict Behav       Date:  2019-04-26       Impact factor: 3.913

10.  Sex differences in the influence of nicotine dose instructions on the reinforcing and self-reported rewarding effects of smoking.

Authors:  Kenneth A Perkins; Todd Doyle; Melinda Ciccocioppo; Cynthia Conklin; Michael Sayette; Anthony Caggiula
Journal:  Psychopharmacology (Berl)       Date:  2005-08-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.